Get the Stockscreener App
21.99
1.20%
0.26
After Hours:
22.15
0.16
+0.73%
Cidara Therapeutics Inc Stock (CDTX) Latest News
Bullish On Cidara Therapeutics As It Doubles Down On CD388 For Universal Flu Prevention - Seeking Alpha
(CDTX) Trading Signals - Stock Traders Daily
Cidara Therapeutics (NASDAQ:CDTX) Stock Rating Upgraded by Cantor Fitzgerald - MarketBeat
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Short Interest Up 113.6% in January - MarketBeat
Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
Inside Cidara's Next Move: CEO Jeffrey Stein Takes Center Stage at Elite Biotech Conference - StockTitan
Long Term Trading Analysis for (CDTX) - Stock Traders Daily
Cantor Fitzgerald raises Cidara stock to Overweight - MSN
Cidara Therapeutics’ (CDTX) “Overweight” Rating Reaffirmed at Cantor Fitzgerald - Defense World
Cantor Fitzgerald raises Cidara stock to Overweight By Investing.com - Investing.com Canada
Cidara Therapeutics (NASDAQ:CDTX) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Cidara Therapeutics (NASDAQ:CDTX) Share Price Passes Above 50 Day Moving AverageWhat's Next? - MarketBeat
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives $32.20 Consensus Price Target from Analysts - MarketBeat
Contrasting Cidara Therapeutics (NASDAQ:CDTX) and Kodiak Sciences (NASDAQ:KOD) - Defense World
Here’s Why Cidara Therapeutics, Inc. (CDTX) Is Skyrocketing - MSN
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Short Interest Update - MarketBeat
Why These 24 Stocks Are Skyrocketing - Insider Monkey
Geode Capital Management LLC Buys 9,771 Shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX) - Defense World
(CDTX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Cidara Therapeutics (NASDAQ:CDTX) Shares Cross Above 50 Day Moving AverageTime to Sell? - MarketBeat
Cidara Therapeutics announces board changes, CMO separation - Investing.com
Cidara Therapeutics Announces Leadership Changes and Appointments - MSN
Cidara Therapeutics, Inc. Announces Management Changes - Marketscreener.com
Aspergillosis Market Expected to rise, 2034 | Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, I - The Globe and Mail
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives $32.20 Average PT from Analysts - Defense World
Cidara Therapeutics stock soars to 52-week high of $24.99 By Investing.com - Investing.com Nigeria
Cidara Therapeutics stock soars to 52-week high of $24.99 - Investing.com
(CDTX) Proactive Strategies - Stock Traders Daily
Analysts Set Cidara Therapeutics, Inc. (NASDAQ:CDTX) PT at $32.20 - MarketBeat
Influenza A Infections Market Overview: Size, Share, and Future - openPR
Cidara Therapeutics files to sell 7.04M shares of common stocks by selling shareholders - MSN
Cidara Therapeutics (CDTX) Just Flashed Golden Cross Signal: Do You Buy? - MSN
Cidara Therapeutics stock soars to 52-week high of $24.4 - Investing.com
Cidara Therapeutics (NASDAQ:CDTX) versus Ginkgo Bioworks (NYSE:DNA) Financial Survey - Defense World
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Large Increase in Short Interest - MarketBeat
Cidara Therapeutics (NASDAQ:CDTX) Coverage Initiated at Royal Bank of Canada - Defense World
RBC Capital Initiates Coverage of Cidara Therapeutics (CDTX) with Outperform Recommendation - MSN
Cidara Therapeutics (NASDAQ:CDTX) Now Covered by Analysts at Royal Bank of Canada - MarketBeat
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):